• Users Online: 52
  • Print this page
  • Email this page
Year : 2021  |  Volume : 10  |  Issue : 1  |  Page : 112-115

Anti-CD6 humanized monoclonal antibody itolizumab, halts disease progression and severity of acute respiratory distress syndrome in COVID-19 disease: A case study

1 Department of General Medicine, Bhatia Hospital, Mumbai, Maharashtra, India
2 Department of Critical Care Medicine, Bhatia Hospital, Mumbai, Maharashtra, India

Correspondence Address:
Dr. Hemant P Thacker
Bhatia Hospital, Tardeo Road, Old Chikalwadi, Grant Road (W), Tardeo, Mumbai - 400 007, Maharashtra
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/ijrc.ijrc_78_20

Rights and Permissions

In COVID-19 patients, cytokine release syndrome plays a critical role in disease progression. Itolizumab inhibits T-cell proliferation and differentiation, thereby modulating imminent cytokine storm. Here, we report a case of a 44-year-old male patient with confirmed COVID-19 and oxygen saturation (SpO2) of 88% on room air. A chest X-ray revealed dense opacification. High levels of inflammatory markers such as C-reactive protein (CRP) and ferritin were observed. The patient's SpO2 decreased to 87% on day 4 despite the best supportive care. Itolizumab was then administered at 1.6 mg/kg along with high flow oxygen. The patient's SpO2 values improved to 95% and 97% on 4th- and 5th-day postinfusion, respectively. CRP and ferritin levels decreased by 85.96% and 24.48%, respectively, along with radiological improvement. The patient was discharged on the 7th day postinfusion in a clinically stable condition. This is the first report of an anti-CD6 humanized monoclonal antibody, itolizumab, given to a patient with moderate-to-severe COVID-19 disease that showed a reduction in hyperinflammation, leading to clinical and radiological improvement.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded18    
    Comments [Add]    

Recommend this journal